- Preclinical study to be presented at WCO conference shows no pyrogenicity
- Pivotal clinical trial in osteoarthritis patients on track to start in 2025
Liege, Belgium – 11 April 2025 (17:00 CET) – Allegro NV, a biomedical company developing transformative nanotechnology-based treatments for osteoarthritis, today presented positive preclinical data demonstrating the satisfactory safety profile of its hydrocelin injectable treatment for osteoarthritis at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO) in Rome. The study, which showed that hydrocelin is non-pyrogenic, was part of a series of preclinical tests into several safety aspects for the product, all of which have yielded a satisfactory profile.
“Presenting the positive results of our preclinical safety studies with hydrocelin at WCO is important recognition of the work we are doing to apply new technologies to the treatment of osteoarthritis. The unique cross-linking properties of hydrocelin make us believe there is huge potential to help alleviate the pain and suffering of people with osteoarthritis. As Allegro’s next milestone is the start of a pivotal trial in patients, which we expect later this year, we hope to quickly see our vision confirmed,” said Lucas Decuypere, Chief Executive Officer at Allegro.
Hydrocelin contains cross-linked microparticles that are designed to act as tiny shock absorbers in the synovial fluid of the affected joints. Restoring the shock-absorbing capacity of the synovial fluid is intended to provide pain relief and protect cartilage. The device is intended to be implanted by injection once yearly. In addition to the pyrogenicity study, the company has also found a satisfactory safety record in preclinical studies assessing irritation, delayed sensitization and systemic toxicity.
Poster presentation details:
Title: Pyrogenicity assessment of crosslinked hydrogel microparticles (HMPs) utilizing the rabbit pyrogen test in accordance with European pharmacopoeia guidelines
Session time and date: Friday April 11, 2025: 09:00 – 17:00 Poster viewing session I
Lead authors: J. Schelfhout and B. Gür
Poster presentation number: P293